The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2021 | Adjuvant chemotherapy in gastric adenocarcinoma
Lei Deng, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses the prognostic and predictive role of preoperative chemotherapy sensitivity in gastric adenocarcinoma. 2,300 patients with gastric adenocarcinoma in the National Cancer Database were analyzed, with chemosensitivity used as a predicative biomarker. The survival benefit from administering adjuvant chemotherapy depended on the sensitivity to preoperative chemotherapy, where those who have achieved lower stage had improved survival from adjuvant chemotherapy, but those who had refractory disease or pathological complete response did not. Chemosensitivity was additionally effective as a prognostic biomarker. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.
